Cequent Pharmaceuticals

Cequent, which was acquired by Marina Biotech in 2010, developed new, clinically compatible therapies based on RNA interference (RNAi) therapies. The company focused its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.

Cequent Pharmaceuticals

Cambridge, MA

04.15.2010
Cequent begins chronic toxicology study

Read More

04.15.2010
Cequent begins chronic toxicology study

Read More